Application of gold-catalyzed hydroamination in sialic acids for the cancer-localized in vivo release of an immunotherapy drug

金催化唾液酸氢氨化在免疫治疗药物癌症局部体内释放中的应用

基本信息

批准号：
21K05302
负责人：
張宗哲
金额：
$ 2.66万
依托单位：
Institute of Physical and Chemical Research
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2021
资助国家：
日本
起止时间：
2021-04-01 至 2024-03-31
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-21K05302/
关键词：
Sialyltransferase Prodrug Acrolein In vivo synthesis Gold metal Immunotherapy Metal catalysis Sialic acid Glycoalbumin

项目摘要

One of the glycan moieties generally overexpressed in cancer are sialic acids, which can induce immunomodulatory properties via binding to Siglec receptors. Therapies are being proposed and tested in animal models that aim to decrease sialic acid on cancer cells that are crucial for maintaining the inflammatory environment in tumors. However, sialyltransferase inhibitors that have been reported to reduce the amount of sialic acid are not selective for cancer cells and could cause side effects such as kidney dysfunction and weight loss. Recently our laboratory found that acrolein is expressed in large amounts in cancer cells. Furthermore, our laboratory has developed a prodrug that can be activated selectively by the reaction with acrolein of cancer cells. Herein, this author attempted to deliver a sialyltransferase inhibitor selectively to the cancer cells by using the [3+2] cycloaddition of azide and acrolein. A prodrug was synthesized by conjugating the hydroxyl group of the sialyltransferase inhibitor with 2, 6-diisopropylphenyl azide via a carbonyl linker. The prodrug reacts with endogenous to give a diazo compound, which subsequently cleave the linker and release of the sialyltransferase inhibitor only in cancer cells.

通常在癌症中过度表达的聚糖部分是唾液酸，可以通过与SIGLEC受体结合诱导免疫调节特性。正在提出和测试动物模型中的疗法，旨在减少唾液酸对维持肿瘤炎症环境至关重要的癌细胞。然而，据报道降低唾液酸量的促溶解酶抑制剂对癌细胞没有选择性，并且可能引起副作用，例如肾脏功能障碍和体重减轻。最近，我们的实验室发现丙烯醛在癌细胞中大量表达。此外，我们的实验室已经开发了一种前药，可以通过与癌细胞的丙烯醛反应有选择地激活该前药。本文中，作者试图通过使用叠氮化物和丙烯醛的[3+2]环加成对癌细胞的选择性地传递siallyltransferase抑制剂。通过通过羰基连接器与2个，6-二异丙基苯基叠氮化物结合羟基转移酶抑制剂的羟基来合成前药。前药与内源性反应，得到重氮化合物，随后仅在癌细胞中裂解接头并释放siallyltransferase抑制剂。